Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

568 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Edaravone and its clinical development for amyotrophic lateral sclerosis.
Takei K, Watanabe K, Yuki S, Akimoto M, Sakata T, Palumbo J. Takei K, et al. Among authors: akimoto m. Amyotroph Lateral Scler Frontotemporal Degener. 2017 Oct;18(sup1):5-10. doi: 10.1080/21678421.2017.1353101. Amyotroph Lateral Scler Frontotemporal Degener. 2017. PMID: 28872907 Review.
Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients.
Abe K, Itoyama Y, Sobue G, Tsuji S, Aoki M, Doyu M, Hamada C, Kondo K, Yoneoka T, Akimoto M, Yoshino H; Edaravone ALS Study Group. Abe K, et al. Among authors: akimoto m. Amyotroph Lateral Scler Frontotemporal Degener. 2014 Dec;15(7-8):610-7. doi: 10.3109/21678421.2014.959024. Epub 2014 Oct 6. Amyotroph Lateral Scler Frontotemporal Degener. 2014. PMID: 25286015 Free PMC article. Clinical Trial.
Edaravone for treatment of early-stage ALS - Authors' reply.
Akimoto M, Nakamura K; Writing Group on behalf of the Edaravone (MCI-186) ALS 19 Study Group. Akimoto M, et al. Lancet Neurol. 2017 Oct;16(10):772. doi: 10.1016/S1474-4422(17)30290-9. Epub 2017 Sep 12. Lancet Neurol. 2017. PMID: 28920878 No abstract available.
A Randomized, Single-Blind, Placebo-Controlled, 3-Way Crossover Study to Evaluate the Effect of Therapeutic and Supratherapeutic Doses of Edaravone on QT/QTc Interval in Healthy Subjects.
Shimizu H, Inoue S, Endo M, Nakamaru Y, Yoshida K, Natori T, Kakubari M, Akimoto M, Kondo K. Shimizu H, et al. Among authors: akimoto m. Clin Pharmacol Drug Dev. 2021 Jan;10(1):46-56. doi: 10.1002/cpdd.814. Epub 2020 Jun 15. Clin Pharmacol Drug Dev. 2021. PMID: 32543120 Free PMC article. Clinical Trial.
Pharmacokinetics of Edaravone Oral Suspension in Patients With Amyotrophic Lateral Sclerosis.
Shimizu H, Nishimura Y, Shiide Y, Akimoto M, Yashiro M, Ueda M, Hirai M, Yoshino H, Mizutani T, Kanai K, Kano O, Kimura H, Sekino H, Ito K. Shimizu H, et al. Among authors: akimoto m. Clin Ther. 2023 Dec;45(12):1251-1258. doi: 10.1016/j.clinthera.2023.09.025. Epub 2023 Nov 11. Clin Ther. 2023. PMID: 37953075 Free article. Clinical Trial.
Successful Pregnancy and Delivery After Frozen-thawed Embryo Transfer Following the Third Discontinuation of Tyrosine Kinase Inhibitor in a Woman with Chronic Myeloid Leukemia.
Takayama K, Fujisawa S, Sakuma T, Hasegawa K, Katsuki K, Akimoto M, Matsumura A, Nakajima Y, Miyazaki T, Murase M, Nakajima H. Takayama K, et al. Among authors: akimoto m. Intern Med. 2024 Apr 9. doi: 10.2169/internalmedicine.3322-23. Online ahead of print. Intern Med. 2024. PMID: 38599867 Free article.
568 results